White House officials on June 23, 2026, denied a report that President Trump received access to the retatrutide weight-loss drug through the Food and Drug Administration's (FDA) compassionate use program. The drug, manufactured by Eli Lilly, is not FDA approved. According to the report, an unnamed individual accessed the prescription through a different program.
✓ AI-Debiased Article
30
Mainstream framing
provisional
Why this rating? · 1 signal
Signals flagged in the original
- headline asserts a conclusion / scare-quotes
Provisional estimate — refines shortly Full breakdown ↓
White House denies report on Trump's access to Eli Lilly obesity drug
The White House has refuted claims that President Trump accessed the retatrutide weight-loss drug via the FDA's compassionate use program. The drug, produced by Eli Lilly, is not currently approved by the FDA.
Companies
Eli Lilly
People
President Trump
Annotating as
No note attached
on this article.
Bias Analysis
Bias score
30/100
wirepublicmainstream
flavoredpartisanadvocacy
Inflammatory language
10/100
Bias Indicators Removed
- ✕ headline asserts a conclusion / scare-quotes
Original vs. Neutral
Original Headline
White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
Neutral Headline
White House denies report on Trump's access to Eli Lilly obesity drug